FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
N-Glycan Analysis of Infliximab-dyyb
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.
Glycosylation of biologics during recombinant synthesis must be fully characterized for therapeutic development. Employing a Biozen Glycan LC column for a HILIC-mode separation of released N-glycans is an effective protocol.